One of the most visible goldfish health problems has a very common cause. Take our advice to find out what to do if your goldfish starts to turn upside down. What is this problem and how can I ...

If you frequently wake up to go to the bathroom during the night, you may have nocturia. Nocturia refers to having an overactive bladder at night, and can be frustrating and difficult to live with – ...

Bladder control problems, or urinary incontinence, can cause an uncontrolled urgency to urinate, increased visits to the bathroom, and accidental leakage. Different medical conditions, aging, and ...

Overactive bladder (OAB) is a group of symptoms that are not usually life-threatening but can significantly decrease productivity and quality of life. The condition is characterized by the sudden need ...

Michael Menna, DO, is currently an attending emergency medicine physician at White Plains Hospital in White Plains, New York, with nearly 10 years of experience. Rich Scherr is an updates ...

Botox is a prescription drug that’s used to treat certain bladder problems, such as overactive bladder (OAB) in adults. For certain bladder problems, Botox may also be prescribed to children ...

Ultrasound is a non-invasive imaging technique that uses the differential reflectance of acoustic waves at ultrasonic frequencies to detect objects and measure distances. It is commonly used for ...

Oct 18 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the ...

After falling short in a confirmatory clinical trial, Gilead Sciences has decided to withdraw Trodelvy as a bladder cancer treatment in the U.S. The California biotech announced the decision ...

But that drug is primarily used to treat blood cancers like lymphoma, while Trodelvy is aimed at a variety of solid tumors. The setback in bladder cancer is a small disappointment, representing less ...

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for bladder cancer in 2021, failed its confirmatory trial earlier this year. Gilead ...